Business / Finance

RSS

IntriCon reports net sales of $15 million in fourth quarter 2013

IntriCon Corporation, a designer, developer, manufacturer and distributor of miniature and micro-miniature body-worn devices, today announced financial results for its fourth quarter and year ended December 31, 2013.

20 Feb 2014

Toshiba announces full suite of healthcare solutions

Toshiba's Digital Products Division (DPD), a division of Toshiba America Information Systems, Inc., today announced a full suite of healthcare solutions, which provide the accuracy, efficiency and innovation that healthcare organizations need to deliver the next generation of patient care.

19 Feb 2014

iCAD total revenue for Q4 2013 increases 16.8% to $9.1 million

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2013.

19 Feb 2014

DUKAL, Vancive Medical Technologies ink distribution agreement for BeneHold Absorbent Wound Dressings

Vancive Medical Technologies and DUKAL Corporation today announced an agreement for the distribution of the Vancive BeneHold Absorbent Wound Dressing range in the United States and Canada. The BeneHold range includes the Thin Absorbent Wound Dressing, the Standard Hydrocolloid Dressing and the Bordered Hydrocolloid Dressing with Odor Control.

18 Feb 2014

NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013

NPS Pharmaceuticals, Inc., a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today reported financial results for 2013 and its financial outlook for 2014.

18 Feb 2014

HealthStream fourth quarter 2013 revenues up 33%

HealthStream, Inc., a leading provider of workforce development (which we have previously referred to as "learning and talent management") and research / patient experience solutions for the healthcare industry, announced today results for the fourth quarter and full year ended December 31, 2013.

18 Feb 2014

LCA-Vision revenues increase 2.1% to $20.6 million in Q4 2013

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus brand, today announced financial and operating results for the three and 12 months ended December 31, 2013.

18 Feb 2014

MAXIMUS Foundation distributes grants to 87 local non-profit organizations

MAXIMUS, a leading provider of government services worldwide, announced today that the MAXIMUS Foundation has distributed approximately $206,000 in grants to 87 local non-profit organizations as part of its most recent grant cycle.

18 Feb 2014

Acerde and a China-based medical imaging giant ink development contract

Acerde, an innovative company specializing in the development of rotating anodes for X-ray tubes used in the medical imaging industry, today announced (i) the signature of a development contract with a major China-based player in medical imaging, (ii) its achievement of a number of industrial development milestones and (iii) the preparation of the company's next generation of highly innovative rotating anodes (which are now composite-based rather than graphite-based).

18 Feb 2014

Novimmune closes Series B financing for CHF 60 million

Novimmune SA announced that it has closed a Series B financing for CHF 60 million ($66 million). London-based Rosetta Capital Limited led the round with participation of new private investors as well as existing investors.

18 Feb 2014

Polyplus-transfection grants research license to NIH for PEI-mediated transfection applications

Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, announces today that it has granted two agencies of the United States National Institutes of Health a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases and the National Cancer Institute.

17 Feb 2014

Advanced Accelerator Applications successfully completes capital increase of €41 million

Advanced Accelerator Applications, a fast growing international specialist in Molecular Nuclear Medicine (MNM), announced today that it had successfully completed a capital increase of €41 million.

17 Feb 2014

Novartis acquires CoStim Pharmaceuticals

MPM Capital and Atlas Venture announced today that portfolio company CoStim Pharmaceuticals, Inc. has been acquired by Novartis for an undisclosed amount. CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

17 Feb 2014

Horizon Discovery, Sirion Biotech ink supply and distribution agreement

Horizon Discovery, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has signed a supply and distribution agreement with Sirion Biotech GmbH.

17 Feb 2014

BMG Pharma signs agreement with Samyang Biopharmaceutical to market GelX in South Korea

BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with Samyang Biopharmaceutical Corporation granting them the rights to promote, sell and market its novel mucositis management product GelX in the territory of South Korea.

17 Feb 2014

TPI announces financial results for second quarter fiscal year 2014

Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the second quarter fiscal year 2014.

14 Feb 2014

GNC Holdings reports consolidated revenue of $613.7 million in Q4 2013

GNC Holdings, Inc., a leading global specialty retailer of health and wellness products, today reported its financial results for the quarter and year-to-date period ended December 31, 2013.

13 Feb 2014

Fluidigm acquires DVS Sciences

Fluidigm Corp. today announced it has completed its acquisition of DVS Sciences, Inc. With the closing of the acquisition, Fluidigm adds a high-parameter single-cell protein analysis platform to its industry-leading single-cell genomics platforms to create a comprehensive portfolio of advanced technologies serving the rapidly growing single-cell genomics and proteomics markets.

13 Feb 2014

Healthways reports net loss of $5.3 million in Q4 2013

Ben R. Leedle, Jr., president and chief executive officer of Healthways, Inc., today announced financial results for the fourth quarter and year ended December 31, 2013. Total revenues for the quarter were $169.2 million compared with $175.2 million for the fourth quarter of 2012.

13 Feb 2014

Prothelia, University of Nevada, Reno and Alexion partner to develop Laminin-111 for MDC1A

Prothelia Incorporated and University of Nevada, Reno announce that they have entered into strategic agreements with Alexion for the development of Laminin-111, a patented experimental protein replacement therapy for merosin-deficient congenital muscular dystrophy (MDC1A), a life-threatening, ultra-rare disease caused by a genetic deficiency of the Laminin-211 protein.

13 Feb 2014